Session IV. Ethical, liability and regulatory issues

Vaccine

Volumn 21, Issue 24, 2003, Pages 3501-3502

  Glezen, W Paul ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; TETANUS TOXOID; VACCINE;

CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; DRUG DEVELOPMENT; DRUG FATALITY; DRUG INDUSTRY; DRUG MONITORING; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE SYSTEM; HUMAN; IMMUNIZATION; INFLUENZA; INFLUENZA VIRUS; LICENSING; MATERNAL MORTALITY; MEDICAL ETHICS; NEWBORN DEATH; NEWBORN TETANUS; PERINATAL PERIOD; PNEUMONIA; PREGNANCY; PRIORITY JOURNAL; SEPSIS; SIDE EFFECT; STREPTOCOCCUS INFECTION; VACCINE PRODUCTION;

EID: 0037707970     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(03)00398-0     Document Type: Conference Paper

References (8)

1. Glezen W.P. Editorial: prevention of neonatal tetanus. Am. J. Public Health. 88:1998;871-872.
2. Heinonen OP, Slone D, Shapiro S. Immunizing agents. Birth defects and drugs in pregnancy. Littleton (MA): Publishing Sciences Group, Inc.; p. 314-21.
3. Glezen W.P. Maternal vaccines. Primary Care: Clin. Office Pract. 28:2001;791-806.
4. Shahab SZ, Glezen WP. Influenza virus. In: Gonik B, editor. Viral diseases in pregnancy. New York: Springer-Verlag; 1994. p. 215-23.
5. Neuzil K.M., Reed G.W., Mitchel E.F., Simonsen L., Griffin M.R. Impact of influenza on acute cardiopulmonary hospitalizations in pregnant women. Am. J. Epidemiol. 148:1998;1094-1102.
6. Miller H.I., Conko G. Precaution (of a sort) without principle. Priorities for Health. 13:2001;5-39.
7. Michaud C.M., Murray C.J.L., Bloom B.R. Burden of disease - implications for future research. JAMA. 285:2001;535-539.
8. Duranson E. Protection of newborns through maternal immunization. Session IV. Ethical, liability and regulatory, this issue.